Ifex — Competitive Intelligence Brief

Ifex (IFOSFAMIDE) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Alkylating Drug [EPC]. Area: Oncology.

marketed Alkylating Drug [EPC] Oncology Small molecule

Target snapshot

Ifex (IFOSFAMIDE) — Baxter. Ifosfamide is activated by liver enzymes to form cytotoxic compounds that cause DNA crosslinks, leading to cell death.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Ifex TARGET	IFOSFAMIDE	Baxter	marketed	Alkylating Drug [EPC]		1988-01-01
Pepaxto	MELPHALAN FLUFENAMIDE	Oncopeptides Ab	marketed	Alkylating Drug		2021-01-01
Zepzelca	LURBINECTEDIN	Jazz Pharmaceuticals	marketed	Alkylating Drug [EPC]		2020-01-01
Yondelis	TRABECTEDIN	Janssen Prods	marketed	Alkylating Drug [EPC]	Proto-oncogene tyrosine-protein kinase Src	2015-01-01
Treanda	BENDAMUSTINE	Baxter	marketed	Alkylating Drug	Histone deacetylase 6	2008-01-01
Temodar	temozolomide	Merck & Co.	marketed	Alkylating Drug [EPC]		1999-01-01
Hexalen	ALTRETAMINE	Eisai	marketed	Alkylating Drug	Cytochrome P450 1A2	1990-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

• 2032-04-25 — Pepaxto · 10285946 · US
• 2032-04-25 — Pepaxto · 10322182 · US
• 2032-04-25 — Pepaxto · 10543274 · US
• 2032-04-25 — Pepaxto · 10869928 · US
• 2032-04-25 — Pepaxto · 11344622 · US

Sponsor landscape (Alkylating Drug [EPC] class)

1. · 3 drugs in this class
2. Waylis · 2 drugs in this class
3. Baxter · 1 drug in this class
4. Bayer · 1 drug in this class
5. Janssen Prods · 1 drug in this class
6. Jazz Pharmaceuticals · 1 drug in this class
7. Kyowa Kirin Co., Ltd. · 1 drug in this class
8. Merck & Co. · 1 drug in this class
9. Recordati · 1 drug in this class
10. Teva · 1 drug in this class